These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 18617908

  • 21. Glaucoma medications and mortality: a retrospective cohort study.
    French DD, Margo CE.
    Ann Epidemiol; 2010 Dec; 20(12):917-23. PubMed ID: 21074106
    [Abstract] [Full Text] [Related]

  • 22. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.
    Stjernschantz J.
    Adv Prostaglandin Thromboxane Leukot Res; 1995 Dec; 23():63-8. PubMed ID: 7732906
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Brandt JD, Beiser JA, Gordon MO, Kass MA, Ocular Hypertension Treatment Study (OHTS) Group.
    Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.
    Stewart WC, Leech J, Sharpe ED, Kulze J, Ellyn J, Day DG.
    Am J Manag Care; 2002 Aug; 8(10 Suppl):S240-8. PubMed ID: 12188166
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
    Gallagher AM, Leighton-Scott J, van Staa TP.
    Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AG, Lee WH, Rieser JC, Chopra H, Holmes KT.
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S, Mundorf TK, Stewart JA, Stewart WC.
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A, Mohammed Ramez O, Burchert M, Kimmich F.
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.